Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-12-2001 | Paper Report

GW5638: a new antiestrogen

Author: Fatima Cardoso

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

Approximately two-thirds of breast tumors are ER-positive (ER+), and therefore suitable for some type of endocrine therapy. Tamoxifen has been the standard hormonal therapy for the last 30 years. Nevertheless, less than two-thirds of ER+ tumors respond to tamoxifen, and eventually the majority of advanced tumors develop resistance to the drug. Even when the new hormonal agents are used, sublines of resistant cells may develop. Clearly, no single endocrine therapy will be enough to treat all ER+ breast cancer patients and new agents are needed. The authors tested GW5638 for potential activity against breast cancer. …
Literature
1.
Connor CE, Norris JD, Broadwater G, Willson TM, Gottardis MM, Dewhirst MW, McDonnell DP: Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce conformational changes in the estrogen receptor. Cancer Res . 2001, 61: 2917-2922.PubMed
Metadata
Title
GW5638: a new antiestrogen
Author
Fatima Cardoso
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2001-68484

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Paper Report

Enhanced activity of anti-Lewisyhumanised 3S193 when combined with Taxol

Paper Report

Breast cell interactions within a 3D model culture system

Paper Report

Tailored versus high-dose chemotherapy as adjuvant breast cancer treatment

Paper Report

HOXA5 regulation of p53 in breast tumours

Paper Report

Tamoxifen, angiogenesis, oestrogens and animal models

Paper Report

Multigene expression patterns predict metastatic behavior
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits